Channel Therapeutics Corporation Stock Price, News & Analysis

Pelthos Therapeutics (NYSE:PTHS) has completed its merger with Channel Therapeutics and secured a $50.1 million private placement. The combined company will begin trading on the NYSE American exchange under the ticker PTHS on July 2, 2025.

The private placement, led by Murchinson Ltd., includes the cancellation of $18.8 million in bridge capital. Pelthos will focus on launching ZELSUVMI™, an FDA-designated novel drug for molluscum contagiosum infections, which affects approximately 16.7 million people in the United States. The medication is the first prescription treatment that can be administered at home.

The company will also evaluate NaV 1.7 development programs for various pain treatments. Scott Plesha will serve as CEO, while former Channel Therapeutics CEO Frank Knuettel II becomes CFO of the combined entity.

Channel Therapeutics (NYSE American: CHRO), a non-opioid pain treatment therapeutics company, announced a 10-for-1 reverse stock split effective July 1, 2025. The split coincides with the company's merger with LNHC and a $50.1 million private placement led by Murchinson.

The reverse split will reduce outstanding shares from approximately 6.48 million to 648,501. Following the merger, the company will be renamed to Pelthos Therapeutics and trade under the symbol "PTHS". The move aims to increase the stock price and meet NYSE American listing requirements.

Channel Therapeutics (NYSE: CHRO) has announced positive results from two preclinical animal trials for its eye drop formulation CT2000, targeting both acute and chronic ocular pain. The first trial demonstrated CT2000's effectiveness in treating acute eye pain using a capsaicin model, showing significant pain reduction within 15 minutes. The second trial, using a dry eye disease model, showed cumulative efficacy over a 7-day treatment period.

The company's NaV1.7 inhibitor showed promising results in both trials, supporting its potential broad applications in pain treatment. The global chronic ocular pain market, valued at $7.2 billion in 2023, is projected to reach $12.44 billion by 2032, growing at a CAGR of 6.6%. The acute eye pain market is valued at $404 million. These successful preclinical results pave the way for Channel to initiate Phase 1/II human proof of concept trials.

Channel Therapeutics (NYSE American: CHRO), a company focused on developing non-opioid pain treatment therapeutics, announced that its 2024 Annual Report filed on March 27, 2025, included an audit opinion with a going concern emphasis of matter paragraph from its independent registered public accounting firm. This disclosure is required by NYSE American LLC Company Guide Sections 410(h) and 610(b). The company clarified that this announcement does not represent any changes or amendments to their consolidated financial statements or their 2024 Annual Report.

Channel Therapeutics (NYSE: CHRO) has provided insights on the differences between NaV1.7 and NaV1.8 pain signal inhibitors, following Vertex Pharmaceutical's Phase 2 data announcement for Suzetrigine. The company emphasizes that while both are voltage-gated sodium channels in sensory neurons, NaV1.7 overexpression leads to more severe pain compared to NaV1.8's moderate pain effects.

Channel is pursuing a three-pronged approach with their NaV1.7 inhibitor: an oral treatment for neuropathic pain, an eye drop formulation for eye pain, and a slow-release depot formulation for post-surgical nerve blocks. The company expects critical data readouts in 2025 to validate their clinical development strategy.

Channel Therapeutics (NYSE: CHRO) announced positive results from preclinical trials of its NaV1.7 inhibitor nerve block formulations for acute pain. The study demonstrated superior efficacy and duration compared to bupivacaine, the current standard of care. Three out of four formulations showed better efficacy than bupivacaine, with one formulation remaining effective for over four days.

The trials included thermal hyperalgesia and mechanical allodynia tests in rodents, with multiple test arms including placebo, bupivacaine, and four Company formulations. Unlike current nerve block therapies that cause temporary paralysis, the NaV1.7 approach doesn't impact mobility, potentially offering better post-surgical physical therapy options.

The Company is targeting the post-operative global pain market, valued at $2.6 billion in 2023. Results for additional studies on eye drops for various types of eye pain are expected in late January 2025.

Channel Therapeutics (NYSE American: CHRO), formerly Chromocell, announced its name change and reincorporation in Nevada. The company focuses on developing non-opioid pain treatments through sodium channel modulation, specifically targeting NaV1.7. The company provided updates on three therapeutic programs: Depot Program for postoperative nerve blocks showing 96-hour sustained release in animals with pending efficacy results; Eye Pain Program with well-tolerated animal studies and expected Phase II human trials in Q2 2025; and a Chronic Pain program planned for Q1 2025 pending program-specific financing.

Chromocell Therapeutics (NYSE American: CHRO) has unveiled an injectable depot program using peripheral nerve blocks for post-operative pain treatment. The program leverages the company's NaV1.7 molecule, targeting a market of approximately 700,000 total knee replacements and 500,000 shoulder arthroplasties performed annually in the US. The company's drug has shown no addictive properties in four Phase I trials and demonstrated strong efficacy in preclinical models. The program aims to reduce opioid usage and could benefit from NOPAIN Act provisions upon FDA approval.

Chromocell Therapeutics (NYSE American: CHRO), a non-opioid pain treatment developer, has announced its participation in two upcoming investor conferences. CEO Frank Knuettel II will present at the LDMicro Main Event XVII on October 29, 2024, from 10:00-10:25 AM PT in Los Angeles, and at the Spartan Capital Investor Conference on November 4, 2024, from 9:45-10:00 AM ET in NYC.

Both events offer opportunities for one-on-one meetings and networking with institutional investors, industry leaders, and capital market representatives. The LDMicro event focuses on showcasing emerging micro-cap companies, while the Spartan conference brings together public company executives and institutional investors for strategic discussions.